IntelGenX is an oral drug delivery company primarily that focuses on the development and manufacturing of pharmaceutical oral films.
IntelGenx is an oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform. It provides comprehensive pharmaceutical services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP, and regulatory services. IntelGenx’s state-of-the-art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full-service capabilities to its clients.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jan 9, 2023 | Post-IPO Debt | $3M | 1 | ATAI Life Sciences | — | Detail |
Feb 1, 2022 | Post-IPO Debt | $3M | 1 | ATAI Life Sciences | — | Detail |
Mar 15, 2021 | Post-IPO Equity | $12.34M | 1 | ATAI Life Sciences | — | Detail |
Mar 15, 2021 | Post-IPO Debt | $2M | 1 | ATAI Life Sciences | — | Detail |
May 8, 2018 | Post-IPO Equity | $3.20M | — | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
ATAI Life Sciences | Yes | Post-IPO Debt |